Cargando…
Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project
Background and Objectives: The Pfizer-BioNTech (BNT162b2) COVID-19 mRNA vaccine has demonstrated excellent efficacy and safety in phase 3 trials. However, no dialyzed patients were included, and therefore safety data for this patient group is lacking. The aim of the study was to assess the safety an...
Autores principales: | Polewska, Karolina, Tylicki, Piotr, Biedunkiewicz, Bogdan, Rucińska, Angelika, Szydłowska, Aleksandra, Kubanek, Alicja, Rosenberg, Iwona, Rodak, Sylwia, Ślizień, Waldemar, Renke, Marcin, Dębska-Ślizień, Alicja, Tylicki, Leszek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307559/ https://www.ncbi.nlm.nih.gov/pubmed/34357013 http://dx.doi.org/10.3390/medicina57070732 |
Ejemplares similares
-
Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study—The COViNEPH Project
por: Dębska-Ślizień, Alicja, et al.
Publicado: (2021) -
Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose
por: Biedunkiewicz, Bogdan, et al.
Publicado: (2022) -
Local and Systemic Immunity Are Impaired in End-Stage-Renal-Disease Patients Treated With Hemodialysis, Peritoneal Dialysis and Kidney Transplant Recipients Immunized With BNT162b2 Pfizer-BioNTech SARS-CoV-2 Vaccine
por: Piotrowska, Magdalena, et al.
Publicado: (2022) -
Safety and Tolerability of mRNA COVID-19 Vaccines in Kidney Transplant Recipients
por: Ślizień, Zuzanna, et al.
Publicado: (2022) -
Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients
por: Tylicki, Leszek, et al.
Publicado: (2022)